, City Hospital, Birmingham, UK
-
British Journal of Diabetes Vol. 15 No. 2 (2015) - Editorials
Rehabilitation of pioglitazone
Abstract HTML PDF -
British Journal of Diabetes Vol. 15 No. 4 (2015) - Editorials
Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: the optimal combination may be metformin, pioglitazone and empagliflozin
Abstract HTML PDF -
British Journal of Diabetes Vol. 16 No. 2 (2016) - Meeting Reports
This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
Abstract HTML PDF -
British Journal of Diabetes Vol. 16 No. 3 (2016) - Editorials
Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?
Abstract HTML PDF -
British Journal of Diabetes Vol. 17 No. 3 (2017) - Editorials
What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?
Abstract HTML PDF -
British Journal of Diabetes Vol. 19 No. 1 (2019): June 2019 - Editorials
Diabetes medications with cardiovascular protection after HARMONY Outcomes and DECLARE-TIMI 58: could metformin, pioglitazone, SGLT2 inhibitors and long-acting GLP-1 receptor agonists complement each other to save lives by different mechanisms?
Abstract PDF HTML -
British Journal of Diabetes Vol. 20 No. 1 (2020): June 2020 - Editorials
Diabetes medications with cardiovascular protection as we enter a new decade: can SGLT2 inhibitors, long-acting GLP-1 receptor agonists, pioglitazone and metformin complement each other to save lives?
Abstract PDF HTML -
British Journal of Diabetes Vol. 20 No. 2 (2020): December 2020 - Editorials
Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020
Abstract PDF HTML -
British Journal of Diabetes Vol. 20 No. 1 (2020): June 2020 - Original Research
Imeglimin, a novel, first in-class, blood glucose-lowering agent: a systematic review and meta-analysis of clinical evidence
Abstract PDF Erratum HTML -
British Journal of Diabetes Vol. 18 No. 2 (2018): April / May / June 2018 - Guidelines
Managing hyperglycaemia in patients with diabetes and diabetic nephropathy–chronic kidney disease Summary of recommendations 2018
Abstract PDF HTML